The U.S. Food and Drug Administration (FDA) has lifted the clinical hold placed on a Phase 1 trial assessing Cellectis’ investigational CAR T-cell therapy, UCARTCS1A, for the treatment of relapsed or refractory multiple myeloma. In September, the FDA placed a hold on the MELANI-01 trial (NCT04142619) based on safety concerns, after a patient who received the second lowest dose of the therapy died from cardiac arrest. Since then, Cellectis has been working closely with the…
You must be logged in to read/download the full post.
The post FDA Lifts Hold on Phase 1 Trial for Car-T-Cell Therapy UCARTCS1A appeared first on BioNewsFeeds.